Publication | Closed Access

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study

Cardiac MuscleCardiomyopathyOmecamtiv MecarbilCardiovascular DiseaseCardiac MechanicMedicinePhysiologyDiastolic FunctionCardiovascular PhysiologyPublic HealthPharmacologyCardiologyDose-dependent AugmentationCardiac Systolic FunctionCardiovascular Imaging